Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
ViroMissile, Inc.
Angiex, Inc.
Hangzhou DAC Biotechnology Co., Ltd.
3B Pharmaceuticals GmbH
Jonsson Comprehensive Cancer Center
Eli Lilly and Company
NextPoint Therapeutics, Inc.
Agenus Inc.
Prelude Therapeutics
Quadriga Biosciences, Inc.
Ludwig Institute for Cancer Research
MacroGenics
Celgene
OPKO Health, Inc.
CytoMed Therapeutics Pte Ltd
Pfizer
University Health Network, Toronto
Corcept Therapeutics
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Altor BioScience
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
ImmunoFrontier, Inc.
Cellectar Biosciences, Inc.
Pfizer
National Cancer Institute (NCI)
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
InSightec
National Institutes of Health Clinical Center (CC)
Poniard Pharmaceuticals